Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LIO-1: A Phase 1b/2, Open-Label Study to Evaluate the Safety and Efficacy of Lucitanib in Combination With Nivolumab in Patients With An Advanced, Metastatic Solid Tumor

NCT04042116 is registered in ClinicalTrials.gov with Clovis Oncology, Inc. as lead sponsor.

NCT NCT04042116
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04042116 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LIO-1: A Phase 1b/2, Open-Label Study to Evaluate the Safety and Efficacy of Lucitanib in Combination With Nivolumab in Patients With An Advanced, Metastatic Solid Tumor
Lead sponsor
Clovis Oncology, Inc.
Phase
Phase 1/2
Overall status
Suspended
Start date
July 29, 2019
Completion date
January 31, 2024
Enrollment
227 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, gynecologic cancer